Buch, Englisch, Band 75, 290 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 470 g
Proceedings of the Symposium on New Drugs and Devices October 30¿31, 1986, Philadelphia, Pennsylvania
Buch, Englisch, Band 75, 290 Seiten, Paperback, Format (B × H): 155 mm x 235 mm, Gewicht: 470 g
Reihe: Developments in Cardiovascular Medicine
ISBN: 978-1-4612-9232-6
Verlag: Springer US
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
I Epidemiology, Therapeutic Endpoints.- 1. The public health and clinical implications of the national increase in congestive heart failure.- 2. Therapeutic endpoints in the treatment of congestive heart failure with systolic dysfunction.- 3. Evaluation of ventricular function in patients with heart failure: invasive or noninvasive?.- 4. Assessment of neurohormonal parameters in congestive heart failure: determination of sodium and water regulation.- 5. The assessment of quality of life and exercise response in patients with chronic cardiac failure.- Panel Discussion.- II Preclinical Issues and Pro Arrhythmia Definitions.- 6. Animal models of heart failure.- 7. Electrophysiology in congestive heart failure animal models.- 8. Noninvasive evaluation of proarrhythmia.- 9. Criteria for proarrhythmia in patients with congestive heart failure: use of electrophysiologic testing.- Panel Discussion.- III FDA Endpoint Issues.- 10. Are placebo-controlled trials necessary in the evaluation of new therapeutic agents in severe chronic heart failure?.- 11. What the FDA requires for endpoint measures in congestive heart failure studies.- 12. Design of trials to assess safety and effectiveness in Rx of CHF.- Panel Discussion.- IV Therapeutic Strategies.- 13. How does congestive heart failure alter response to drugs?.- 14 Status of vasodilators for heart failure.- 15. Perspectives on the use of new phosphodiesterase inhibitors in the treatment of chronic cardiac failure.- 16. Is there a role for beta-blockers in heart failure patients?.- Panel Discussion.- V Clinical Trial Issues.- 17. What CHF trials have shown to date and what is needed?.- 18. How to study sudden cardiac death as an endpoint in congestive heart failure trials.- 19. Interpretation of clinical trials in patients with congestive heart failure.- Panel Discussion.- Participants.